References
- Jones JL, Coles AJ. Campath-1H treatment of multiple sclerosis. Neurodegener. Dis. 5(1), 27–31 (2008).
- Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253(1), 98–108 (2006).
- Redpath S, Michaelsen T, Sandlie I, Clark MR. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology 93(4), 595–600 (1998).
- Hu Y, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128(2), 260–270 (2009).
- Cox AL, Thompson SA, Jones JL et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35(11), 3332–3342 (2005).
- Jones JL, Anderson JM, Phuah CL et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133(Pt 8), 2232–2247 (2010).
- Boyd K, Dearden CE. Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev. Anticancer Ther. 8(4), 525–533 (2008).
- Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341(8861), 1620–1622 (1993).
- Moreau T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344(8918), 298–301 (1994).
- Hirst CL, Pace A, Pickersgill TP et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J. Neurol. 255(2), 231–238 (2008).
- Coles AJ, Compston DA, Selmaj KW et al.; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786–1801 (2008).
- Coles AJ, Fox E, Vladic A et al. Alemtuzumab more effective than interferon ß-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78(14), 1069–1078 (2012).
- Cohen JA, Coles AJ, Arnold DL et al.; CARE-MS I investigators. Alemtuzumab versus interferon β 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled Phase 3 trial. Lancet 380(9856), 1819–1828 (2012).
- Coles AJ, Twyman CL, Arnold DL et al.; CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled Phase 3 trial. Lancet 380(9856), 1829–1839 (2012).
- Moreau T, Coles A, Wing M et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119(Pt 1), 225–237 (1996).
- Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev. Neurother. 12(3), 335–341 (2012).
- Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119(7), 2052–2061 (2009).
- Selmaj K, Arnold D, Brinar V et al. Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif® in Multiple Sclerosis I (CARE-MS I) (S41.006). Neurology 78(Meeting Abstracts 1), S41.006 (2012).
- Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N. Engl. J. Med. 359(7), 768–769 (2008).